MabionCD20 development path in dialogue with the FDA
- Mabion and Oddifact have successfully submitted documentation to the U.S. Food and Drug Administration, including a request for a Type B Pre-IND meeting concerning the MabionCD20 development path in immune thrombocytopenia.
- The regulatory interaction is intended to address the preclinical program, CMC strategy and clinical development pathway, helping define the requirements for potential progression toward clinical trials.
- This milestone represents a concrete implementation of Mabion’s 2025–2030 strategy, combining further development of the Company’s CDMO business with selective advancement of higher-value biologics projects based on existing scientific expertise, assets and intellectual property.
From Reactivation to a Defined Development Path
The development of MabionCD20 has entered a new stage. Following the decision to reactivate the molecule as a potential innovative biologics for rare diseases, Mabion and our strategic partner Oddifact have moved from evaluating possible therapeutic opportunities to defining a specific indication and initiating formal regulatory interaction with the U.S. Food and Drug Administration (FDA).
MabionCD20 is a rituximab-based anti-CD20 monoclonal antibody originally developed as a biosimilar candidate. Although the original program did not proceed to registration, the work conducted during its development created a substantial scientific and technological foundation around the molecule. Mabion accumulated experience in areas including cell line development, upstream and downstream processing, drug substance manufacturing, analytical characterization and CMC documentation. This makes MabionCD20 a mature biological asset supported by extensive product and process knowledge.
The current strategy is based on using this foundation in a different way. Rather than returning MabionCD20 to the highly competitive biosimilars segment, Mabion and Oddifact have evaluated opportunities to reposition the molecule for rare diseases in which targeting CD20 could address an unmet medical need. Following an assessment of potential indications, immune thrombocytopenia (ITP) was selected as the indication with the greatest potential at the present stage of the project.
ITP is an autoimmune disorder characterized by a reduced platelet count and an increased risk of bleeding. Its pathophysiology is associated with immune-mediated platelet destruction and impaired platelet production, with B cells playing an important role in the autoimmune response. This provides the biological rationale for investigating therapies directed against CD20-positive B cells.
The selection of ITP transformed the reactivation of MabionCD20 from a broad strategic concept into a defined development program. Together, Mabion and Oddifact prepared a proposed clinical MabionCD20 development path and the documentation necessary to approach the FDA.
On August 11, 2026, Mabion received confirmation from Oddifact that the documentation had been successfully submitted to the FDA. This represents an important transition for the program. MabionCD20 is now progressing through a structured development process with a selected therapeutic indication, a proposed regulatory pathway and a clearly defined next milestone.
The project also illustrates the logic behind Mabion’s broader 2025-2030 strategy. While the continued expansion of the CDMO activities remains a fundamental part of its business model, Mabion also intends to selectively develop biological projects with higher potential added value. Existing assets and intellectual property can therefore become a foundation for new development programs, particularly where Mabion’s established biologics expertise can provide a meaningful technological advantage.
MabionCD20 Development Path
The request for a Type B Pre-IND meeting is particularly significant because the transition of a biological molecule toward clinical development depends on much more than demonstrating a promising therapeutic rationale.
One of the main objectives is to obtain FDA feedback regarding the planned preclinical program and to determine whether the proposed scope of studies would be adequate to support subsequent progression toward clinical development. Establishing this scope early can be important for a program such as MabionCD20, where a significant amount of knowledge about the molecule already exists, but the asset is now being developed within a new therapeutic context.
The submission of the documentation to the FDA is a significant milestone in the reactivation of the MabionCD20 project and in the implementation of the Company’s strategy for 2025–2030, which, in addition to the further development of its CDMO operations, also involves the development of innovative biologics projects with higher added value, including projects based on the Company’s existing assets and intellectual property and carried out in collaboration with strategic partners.
The planned FDA consultation is expected to help verify whether the proposed CMC strategy appropriately supports that objective and to identify additional work that may be necessary before a complete application to initiate clinical trials can be prepared.
Integrated Biologics Development Strategy
The MabionCD20 program also has significance beyond the development of a single molecule. It provides a practical example of how Mabion intends to combine its experience as a biologics developer with its growing role as a specialized partner for biopharmaceutical companies.
Over the course of MabionCD20 development, Mabion has built capabilities extending across multiple stages of the biologics lifecycle. These include biological process development, upstream and downstream manufacturing, advanced analytical characterization and CMC-related activities. Today, these competences are increasingly applied within Mabion’s business to support external biopharma programs.
Reactivating MabionCD20 allows our company to apply the same integrated capabilities to its own asset.
This distinction is important because biological development is rarely a sequence of independent technical assignments. Decisions taken during process development can influence analytical requirements. Analytical understanding can determine the ability to demonstrate product consistency. Manufacturing strategy needs to support the intended clinical program, while regulatory objectives ultimately determine whether the collected data form an adequate development package.
The MabionCD20 program brings these elements together within one project.
It also demonstrates the potential value of repositioning mature biological assets. Existing molecules may contain scientific, technological value that can be reconsidered as therapeutic knowledge, regulatory approaches and market conditions evolve. In MabionCD20, the objective is to use accumulated knowledge about the molecule as a starting point for a development program addressing a new clinical need rather than beginning again from an early discovery-stage asset.
The cooperation with Oddifact SAS is an important component of this approach. Oddifact contributes expertise in identifying and evaluating therapeutic opportunities for existing biologics, including the use of its technology and regulatory intelligence to assess potential rare disease indications. Mabion contributes extensive knowledge of MabionCD20 itself together with biologics-development, manufacturing, analytical and CMC capabilities.
Within only a few months of beginning their cooperation in 2026, the partners progressed from an assessment of potential orphan indications to the selection of ITP, development of a proposed clinical program and submission of the documentation required to request a pre-IND meeting with the FDA.
This progression provides a tangible example of Mabion’s strategy being translated into specific development activities.
For the Company, the potential value of the program has several dimensions. Mabion estimates that the annual market potential for treatment with an anti-CD20 monoclonal antibody in immune thrombocytopenia in the United States could be approximately $100 million. At the same time, successful development would allow Mabion to participate in a higher-value innovative biologics project while continuing to expand its core CDMO operations.
For biopharmaceutical partners, the project demonstrates another aspect of our development model. Mabion is applying its expertise to the same types of development decisions faced by its customers when preparing medicines for regulatory evaluation.
The submission to the FDA is the beginning of the next phase. Further development will depend on the FDA’s feedback and regulatory decisions. Future marketing authorization remain subject to significant scientific and regulatory uncertainty. Nevertheless, the milestone establishes an important point on the MabionCD20 development path. An asset that was reactivated only months earlier now has a selected rare disease indication, a proposed preclinical, CMC and clinical strategy, and an initiated regulatory dialogue with the world’s largest pharmaceutical market. For Mabion, it is both a step toward the potential development of an innovative therapy for patients with ITP and a practical confirmation of a broader strategic direction.
Prepared by:
Marketing Specialist